Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Alpha DaRT Elicits Complete Responses in Malignant Skin and Soft Tissue Cancers

January 11th 2022

The diffusing alpha-emitter radiation therapy, Alpha DaRT, was found to elicit complete responses per RECIST v1.1 criteria in 10 patients with malignant skin and soft tissue cancers who are enrolled to an ongoing single-institution pilot feasibility trial.

FDA Accepts IND for RM-1995 Photoimmunotherapy in Advanced Cutaneous or Head and Neck SCC

January 6th 2022

The FDA has accepted an investigational new drug application for the photoimmunotherapy treatment, RM-1995, for patients with advanced cutaneous squamous cell carcinoma or head and neck squamous cell carcinoma.

Neoadjuvant Immuno-oncology in the Treatment of Locally Advanced CSCC

January 3rd 2022

Our discussion closes with the presentation of phase 2 clinical trial data of neoadjuvant cemiplimab in locally regionally advanced cutaneous squamous cell carcinoma.

Clinical Case 3 Scenario

January 3rd 2022

Our final clinical case scenario is presented, and Kevin Emerick, MD, uses his experience to determine a proper course of action.

Using Other Therapies and the Future of Systemic Therapy for the Treatment of Advanced CSCC

January 3rd 2022

Drs In, Cohen, and Bakst discuss the use of other therapies for cutaneous squamous cell carcinoma, as well as what they believe is the future of systemic therapy for this disease.

KEYNOTE-629 Trial and Pembrolizumab

December 20th 2021

Dr In comments on data from the KEYNOTE-629 trial that focused on the use of pembrolizumab as a therapy option for patients with cutaneous squamous cell carcinoma.

Clinical Case 2 Continued

December 20th 2021

Drs Bakst and Cohen close out our second clinical case scenario by providing their thoughts on potential radiation therapy and using cemiplimab.

Dr. Weber Discusses Unmet Needs in Ocular and Mucosal Melanoma

December 15th 2021

Jeffrey S. Weber, MD, PhD, discusses unmet needs in ocular and mucosal melanoma.

Clinical Case 2 Scenario

December 13th 2021

Drs In and Emerick analyze the data from our second clinical case scenario and tell us what they would do if it were their patient.

Radiation Approaches for CSCC and Standard of Care

December 13th 2021

Dr Bakst comments on radiation treatment therapies and the standard of care for cutaneous squamous cell carcinoma.

Dr. Lipson on the Role of ctDNA Testing in Melanoma

December 8th 2021

Evan J. Lipson, MD, discusses the role of circulating tumor DNA testing in melanoma.

FDA Greenlights Companion Diagnostic for BRAF Inhibitors in Melanoma

December 8th 2021

The FDA has approved FoundationOne CDx for use as a companion diagnostic for 2 groups of current a future regulatory-approved treatments in melanoma, including single-agent BRAF inhibitors targeting BRAF V600E mutations and BRAF/MEK combination regimens targeting BRAF V600E or V600K mutations.

Incidence of Cutaneous Squamous Cell Carcinoma

December 6th 2021

Starting the discussion on cutaneous squamous cell carcinoma, Dr Emerick provides insight on signs to look for, as well as risk factors.

Immunotherapy in Basal Cell Carcinoma

December 6th 2021

Two experts provide their thoughts on phase 2 data concerning the use of cemiplimab for treating locally advanced basal cell carcinoma.

Ripretinib Demonstrates Impressive Efficacy, Durability in Heavily Pretreated KIT-Mutated Melanoma

December 6th 2021

Filip Janku, MD, PhD, discusses the phase 1 study with ripretinib in patients with KIT-mutated or KIT-amplified melanoma.

FDA Approves Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma Following CR

December 3rd 2021

The FDA has approved pembrolizumab for the adjuvant treatment of adult and pediatric patients with stage IIB or IIC melanoma following complete resection.

Tebentafusp Represents a Potential Frontline Therapy for Patients with Uveal Melanoma

December 2nd 2021

Richard D. Carvajal, MD, discusses the need for additional treatment options in patients with rare melanomas, the promise of tebentafusp, and ongoing trials in the pipeline for this patient population.

Dr. Luke on Toxicities With Targeted Therapy Vs Immunotherapy in Melanoma

December 1st 2021

Jason J. Luke, MD, FACP, discusses the toxicities with targeted therapy vs immunotherapy and management strategies for patients with melanoma.

BO-112 Plus Pembrolizumab Improves ORR in Advanced Melanoma After Progression on Anti–PD-1 Therapy

December 1st 2021

The addition of BO-112 to pembrolizumab produced clinical benefit in patients with unresectable malignant melanoma who have experienced disease progression on anti–PD-1 therapy, according to data from the preliminary analysis of the phase 2 SPOTLIGHT-203 trial.

Hedgehog Inhibitors and Basal Cell Carcinoma

November 30th 2021

Ezra Cohen, MD, FRCPSC, FASCO, and Gino K. In, MD, MPH, elaborate on the role hedgehog inhibitors can play when treating patients with basal cell carcinoma.